Magnesium L-threonate is an orally administered magnesium salt of L-threonic acid studied in humans mainly for sleep-related outcomes, cognitive performance, and selected pain-related clinical contexts. (Research)
Human evidence for magnesium L-threonate currently comes from a small number of randomized controlled trials rather than a broad mature literature. The strongest direct-use human research domains are Sleep, Cognitive Health, and Pain and Acute Inflammation, while a narrow rare-disease crossover study in XMEN disease did not show meaningful benefit. Overall evidence remains limited because the source base is small, some studies are formulation-specific, and exact oral dose details are not always clearly extractable from the available source records. (Research) (Research)
Ingredient Snapshot
- Entity: Magnesium L-Threonate
- Chemical or biological class: Magnesium salt of L-threonic acid (Research)
- Endogenous vs exogenous: Exogenous administered compound; magnesium is an essential mineral, while magnesium L-threonate is a formulated magnesium source rather than an endogenous body compound. (Research)
- Primary human research domains: Sleep, Cognitive Health, Pain and Acute Inflammation. (Research) (Research) (Research)
- Common study formats: Randomized, double-blind, placebo-controlled oral intervention trials, plus one randomized crossover rare-disease study. (Research) (Research)
- Pharmacokinetic characterization status: Limited in the cited source set; bioavailability context is discussed in the EFSA safety assessment rather than through a broad human PK literature. (Research) (EFSA)
- Regulatory context (U.S./EU): EU cited sources describe a novel-food safety assessment and application context; no direct ingredient-specific FDA source is present in the cited material for this article. (EFSA) (EFSA)
Research Snapshot
Magnesium L-threonate is a direct-use magnesium formulation with a human literature centered on a few randomized trials rather than a large replicated evidence base. The strongest cited human domains are Sleep-related outcomes, Cognitive Health, and selected pain-related clinical settings, with pain findings mixed across different populations. (Research) (Research) (Research) (Research)
Typical studied oral exposures in the cited human trials include 1 g/day for 21 days and 2 g/day for 6 weeks, while some pain studies report oral magnesium L-threonate use without an exact standalone daily amount clearly extractable from the available PubMed abstract. A main interpretation limit is that the evidence base is small, formulation-specific, and only partly characterized for dose precision and pharmacokinetics in the cited sources. Overall human evidence is best described as early, usable, and still incomplete. (Research) (Research) (Research) (Research)
A narrow crossover study in XMEN disease did not show meaningful improvement in the reported immune-related endpoints, which helps define the current evidence limits rather than the main research identity of the ingredient. This result applies only within the conditions of the cited study. (Research)
Introduction
Magnesium L-threonate is a compound made by binding magnesium to L-threonic acid, a metabolite related to vitamin C breakdown, and it is used as a formulated oral magnesium source in human research. The cited EU safety materials discuss it as a novel-food ingredient and describe magnesium from this source as bioavailable. (Research) (EFSA)
People usually look up magnesium L-threonate because of interest in sleep, memory, attention, and other brain-related outcomes, but the cited human literature also includes pain-related studies and one rare-disease crossover trial. That interest comes mainly from a small set of randomized controlled studies, not from a broad long-term clinical literature. (Research) (Research) (Research)
This article is informational only, describes the ingredient as a biochemical substance studied in human research, and does not provide medical or dosing advice. (Research)
Quick Summary
- Magnesium L-threonate is a magnesium salt of L-threonic acid studied as an orally administered magnesium source rather than as an endogenous body compound. (Research)
- The strongest cited human research areas are Sleep, Cognitive Health, and selected Pain and Acute Inflammation contexts, based mainly on a small number of randomized placebo-controlled trials. (Research) (Research)
- In one 21-day randomized trial, 1 g/day was associated with improved objective sleep-stage measures and some daytime-function outcomes in adults with self-reported sleep problems. (Research)
- In one 6-week randomized trial, 2 g/day was associated with improvements in several cognition measures in healthy adults with dissatisfied sleep, while not all sleep endpoints changed. (Research)
- Pain-related findings are mixed: one cancer-pain trial reported less morphine escalation and less constipation, while one post-breast-surgery trial reported no clear benefit for persistent pain or related outcomes. (Research) (Research)
- A narrow crossover study in XMEN disease did not report meaningful improvement in the main reported immune endpoints. (Research)
- EU cited sources provide novel-food safety context, while no direct ingredient-specific FDA source is present in the cited source set used here. (EFSA) (EFSA)
Human Research Findings by Condition
Sleep
Human research on Sleep is one of the clearest areas studied for magnesium L-threonate. The cited evidence comes from randomized placebo-controlled trials in adults with sleep dissatisfaction or self-reported sleep problems, with improvement reported in some sleep-related outcomes but not uniformly across all endpoints. (Research) (Research)
Dose studied: 1 g/day
Population: Adults aged 35-55 years with self-assessed sleep problems
Duration: 21 days
Study summary:
A randomized, double-blind, placebo-controlled trial evaluated oral magnesium L-threonate in adults with sleep complaints and reported improvement in objective sleep architecture measures along with some daytime-function outcomes compared with placebo. The source also reported that the intervention was well tolerated in the study population.
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Dose studied: 2 g/day
Population: Healthy adults aged 18-45 years with self-reported dissatisfied sleep
Duration: 6 weeks
Study summary:
A randomized, double-blind, placebo-controlled trial assessed Magtein® and reported improvement in some subjective sleep-related measures, although objective sleep outcomes were not broadly different between groups. This finding is limited to the study population and duration.
Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: (Research)
Cognitive Health
Human evidence for Cognitive Health is narrower than the sleep literature and is currently anchored mainly to one randomized placebo-controlled trial. That study reported improvement across several cognitive domains, but the cited source set does not provide broad replication across multiple independent cognitive trials. (Research)
Dose studied: 2 g/day
Population: Healthy adults aged 18-45 years with self-reported dissatisfied sleep
Duration: 6 weeks
Study summary:
A randomized, double-blind, placebo-controlled study evaluated oral magnesium L-threonate and reported improvements in overall cognition, working memory, episodic memory, and reaction time compared with placebo. The cognitive findings were reported in a population selected partly for sleep dissatisfaction, so this result applies only within the conditions of the cited study.
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Pain and Acute Inflammation
Human research in Pain and Acute Inflammation contexts is mixed rather than consistent. One randomized trial in advanced cancer pain reported a lower increase in morphine dose and less opioid-related constipation, while another randomized trial after breast cancer surgery reported no clear benefit for persistent pain or related mood, sleep, and cognition outcomes. (Research) (Research)
Dose studied: Oral magnesium L-threonate; exact daily amount not clearly extractable from the verified source
Population: Advanced cancer patients receiving opioid treatment
Duration: 90 days
Study summary:
A randomized, double-blind, placebo-controlled trial added oral magnesium L-threonate to cancer pain management and reported a smaller increase in morphine dose over time together with improvement in opioid-related constipation versus placebo. Because the available source record does not clearly disclose the exact standalone oral daily amount in the abstract, this should be read as formulation-level clinical evidence rather than a precisely dose-defined trial summary.
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Dose studied: Oral magnesium L-threonate; exact daily amount not clearly extractable from the verified source
Population: Patients after breast cancer surgery
Duration: 12 weeks
Study summary:
A randomized, double-blind, placebo-controlled trial tested oral magnesium L-threonate after breast cancer surgery and reported no significant benefit over placebo for persistent pain prevention, mood, sleep, or cognition outcomes. This evidence does not establish long-term or general-population effects.
Result: Human clinical study reported no clear effect
Evidence strength: Moderate
Study source: (Research)
Immune System
Human evidence for Immune System use is narrow and currently negative in the cited source set. The available study is a randomized crossover trial in XMEN disease linked to MAGT1 deficiency, and it did not report meaningful improvement in the main reported virologic or immune-cell outcomes. (Research)
Dose studied: Oral magnesium L-threonate for 12 weeks, followed by open-label use after 3 days of high-dose IV magnesium sulfate; exact oral dose not clearly extractable from the verified source
Population: Patients with XMEN disease
Duration: 12 weeks oral crossover phase, plus IV/open-label extension
Study summary:
A randomized, double-blind, placebo-controlled crossover study evaluated oral magnesium L-threonate in XMEN disease and found no meaningful improvement in Epstein-Barr virus burden or NKG2D expression, leading to early trial stoppage. The findings are specific to the study design and may not generalize beyond it.
Result: Human evidence remains limited or inconclusive
Evidence strength: Inconclusive
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human exposure data for magnesium L-threonate come mainly from oral intervention trials, with one lower-dose sleep study at 1 g/day, one cognition-focused study at 2 g/day, and several formulation-level clinical studies where the exact standalone oral amount is not clearly extractable from the available abstract. The cited evidence is therefore narrower than a full dose-response literature, and part of the higher-exposure context comes from EU safety materials rather than core efficacy trials. The lowest documented human exposure in the cited study set is 1 g/day, and the overall pattern is better described as a small clinical-use literature than as a mature dose-ranging field. (Research) (Research)
This exposure comes from a 21-day randomized, double-blind, placebo-controlled oral intervention in adults aged 35-55 years with self-assessed sleep problems. The study used magnesium L-threonate as the active intervention and assessed sleep architecture together with daytime-function measures. Researchers reported improvement in several objective sleep-stage measures and some daytime outcomes versus placebo. This is one of the clearest dose-defined trials in the cited source set. It is also one of the main anchors for the ingredient’s sleep-related human evidence. (Research)
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: This dose band is supported by one short-duration trial in a specific adult population.
This exposure comes from a 6-week randomized, double-blind, placebo-controlled oral trial in healthy adults aged 18-45 years with dissatisfied sleep. The formulation was Magtein®, and the study evaluated cognition, working memory, episodic memory, reaction time, and sleep-related outcomes. Several cognitive measures improved, and some subjective sleep-related measures improved, but objective sleep outcomes were not broadly different. This makes the 2 g/day band relevant mainly for cognition-focused and mixed sleep-cognition interpretation rather than for a uniform sleep effect. (Research)
Result: Mixed findings
Evidence strength: Moderate
Notes / limitations: The study population was selected partly for sleep dissatisfaction, so the findings do not establish broader effects in the general population.
This clinical context comes from a 90-day randomized, double-blind, placebo-controlled trial in advanced cancer patients receiving opioids. Magnesium L-threonate was added to pain management, and the reported outcomes included morphine dose escalation and opioid-related constipation. Researchers reported a lower increase in morphine dose over time and improvement in constipation versus placebo. Because the exact standalone oral daily amount is not clearly extractable from the available abstract, this should not be treated as a clean isolated-dose band comparable to the 1 g/day and 2 g/day trials. (Research)
Result: Modest improvement
Evidence strength: Limited
Notes / limitations: This is formulation-level clinical evidence with incomplete public dose detail in the cited source record.
This exposure context comes from a 12-week randomized, double-blind, placebo-controlled trial after breast cancer surgery. The trial assessed persistent pain together with mood, sleep, and cognition outcomes. Researchers reported no significant benefit over placebo across the main reported endpoints. This context is important because it shows that not all pain-related applications produced favorable findings. (Research)
Result: No clear effect
Evidence strength: Moderate
Notes / limitations: The exact standalone oral amount is not clearly extractable from the cited source abstract.
This is a narrow rare-disease exposure context rather than a core general-use dose band. The crossover study used oral magnesium L-threonate for 12 weeks and then included 3 days of high-dose IV magnesium sulfate before open-label oral treatment. No meaningful therapeutic effect was reported for the main immune-related outcomes, and the study was stopped. This context helps define the boundary of the evidence base more than a typical studied-use range. (Research)
Result: Inconclusive
Evidence strength: Emerging
Notes / limitations: This niche clinical context should not be generalized to common-use populations.
This exposure level appears in cited EU novel-food application and safety-assessment materials rather than as core efficacy-trial evidence. The application summary describes proposed use up to 3 g/day, and the EFSA assessment discusses safety and magnesium bioavailability from this source under the proposed conditions of use. This information is useful for safety-context interpretation but should not be read as evidence that 3 g/day is an established efficacy dose. The cited sources also describe exposure context corresponding to about 250 mg magnesium and about 2730 mg L-threonate in the assessment framework. (EFSA) (EFSA)
Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: This is regulatory-context-only exposure information, not a completed efficacy-dose trial band.
Key Takeaways from Human Research
- The clearest human evidence for magnesium L-threonate in the cited source set is in Sleep and Cognitive Health, based on a small number of randomized placebo-controlled trials. (Research) (Research)
- Pain and Acute Inflammation findings are mixed across populations, with one positive signal in advanced cancer pain management and one neutral trial after breast cancer surgery. (Research) (Research)
- The current human literature is small and formulation-bound, and some source records do not clearly disclose exact standalone oral daily doses. (Research) (Research)
- Immune System evidence in the cited rare-disease crossover study did not show meaningful benefit. (Research)
- The cited EFSA materials support EU safety and bioavailability context, but they do not substitute for a broad clinical efficacy literature. (EFSA)
Ingredient Identity
- Official name(s): Magnesium L-threonate
- Synonyms: Magnesium threonate; magnesium L-threonate monohydrate in cited EU application context
- Classification: Magnesium salt of L-threonic acid
- CAS number (if available): Not clearly provided in the cited source set
- Endogenous vs exogenous (if applicable): Exogenous formulated magnesium source
Origin & Natural Occurrence
Magnesium L-threonate is not described in the cited sources as a naturally abundant dietary compound in the way magnesium in foods is. Instead, the cited materials describe it as a manufactured magnesium source made from magnesium and L-threonic acid for direct oral use and regulatory assessment. (Research) (EFSA)
L-threonic acid is relevant because it is associated with vitamin C metabolism, while magnesium itself is an essential mineral required in human biology. In the cited source set, however, the research focus is on the formulated compound magnesium L-threonate rather than on ordinary dietary occurrence. (Research)
How It Behaves in the Body
In plain language, magnesium L-threonate is used as a delivery form for magnesium. The cited safety assessment describes magnesium from this source as bioavailable, meaning the compound can dissociate and provide magnesium that the body can absorb and use. (Research) (EFSA)
More technically, the cited EFSA assessment discusses dissociation behavior and bioavailability evidence drawn from dissociation data, animal work, and one human trial context. That means the best-established point in the cited source set is magnesium availability from the salt, not a fully mapped human mechanistic pathway unique to magnesium L-threonate itself. (Research) (EFSA)
The human trials in sleep, cognition, and pain measured clinical or functional outcomes rather than detailed mechanistic biomarkers. As a result, the cited evidence says more about observed trial outcomes than about a complete human mechanism map for this ingredient. (Research) (Research)
Absorption & Delivery Formats
Oral immediate-release use is the main format represented in the cited human studies. The sleep, cognition, cancer-pain, breast-surgery, and XMEN studies all used oral magnesium L-threonate in intervention settings, although exact formulation details are not always fully visible from the available source records. (Research) (Research)
Evidence for oral extended-release, sublingual, or transdermal magnesium L-threonate is not present in the cited source set. The absence of those formats in the cited materials means no article-level conclusions should be drawn for them here. (Research)
An injectable / IV magnesium exposure appears only in the XMEN study, and that phase used high-dose IV magnesium sulfate rather than IV magnesium L-threonate. This is therefore a clinical context detail, not evidence for an injectable magnesium L-threonate delivery format. (Research)
Quick Facts at a Glance
Onset (reported)
A precise human onset time is not clearly established in the cited source set. The available trials assessed outcomes over 21 days, 6 weeks, 12 weeks, and 90 days, so the literature is better for study-duration context than for exact time-to-effect reporting. (Research) (Research) (Research)
Time to peak (Tmax)
A specific human Tmax for magnesium L-threonate is not clearly reported in the cited source set. The available regulatory and clinical sources discuss bioavailability and study outcomes but do not provide a detailed clinical PK profile with peak-time estimates. (Research) (EFSA)
Half-life (t½)
A specific human t½ for magnesium L-threonate is not clearly extractable from the cited materials. The current source set therefore supports bioavailability context, but not a well-defined elimination half-life for the intact formulation. (Research)
Typical duration
The cited intervention durations range from 21 days to 90 days, with one crossover rare-disease study using a 12-week oral phase before an IV and open-label extension. This indicates that the visible human literature is oriented toward short and medium study periods rather than long-term use characterization. (Research) (Research) (Research)
Absorption routes studied
The main studied route is oral administration. EU cited materials additionally discuss magnesium bioavailability from this source in a safety-assessment framework, but the source set does not provide a broad comparative human absorption literature across multiple delivery routes. (EFSA) (Research)
Formulation differences
Formulation matters because some cited studies clearly specify magnesium L-threonate or Magtein®, while other records do not disclose enough abstract-level detail to reconstruct exact standalone daily dosing. Some findings are therefore best treated as formulation-level evidence rather than fully standardized pure-dose evidence. (Research) (Research)
Variability drivers
The cited source set suggests that variability may come from population differences, study purpose, and outcome type. Sleep-focused adults, healthy adults with dissatisfied sleep, advanced cancer patients, post-surgical patients, and patients with XMEN disease are very different research populations, which limits simple cross-trial comparison. (Research) (Research)
Tolerance / adaptation
Tolerance or adaptation is not characterized as a distinct phenomenon in the cited source set. The available evidence mainly reports short-term tolerability and trial safety rather than progressive loss of effect over time. (Research) (Research)
Evidence strength snapshot
The evidence base is limited but usable, with a few randomized trials, one narrow rare-disease crossover study, and EU safety-assessment material. The strongest human signals are in Sleep and Cognitive Health, pain findings are mixed, and review-level synthesis coverage is absent in the cited source set. (Research) (Research) (EFSA)
Other Physiological Contexts Studied
- A randomized crossover study in XMEN disease examined oral magnesium L-threonate and later IV magnesium sulfate as a rare-disease therapeutic context, but no meaningful improvement was reported in the main EBV or NKG2D outcomes. This remains a narrow disease-specific signal rather than a broad use case. (Research)
- EU safety materials discuss magnesium bioavailability from magnesium L-threonate and use that information for novel-food safety interpretation. This is useful physiological context, but it is not the same as a broad clinical pharmacokinetic literature. (Research) (EFSA)
Safety, Interactions & Regulation
The cited clinical trials generally describe magnesium L-threonate as well tolerated in the studied populations over short study periods. The 21-day sleep trial reported it was safe and well tolerated, and the 6-week cognition-and-sleep trial reported no significant adverse reactions. (Research) (Research)
The cited source set is less complete for long-term safety, rare adverse effects, and formal interaction mapping. In the XMEN study, one participant had asymptomatic liver-enzyme elevation during the IV magnesium sulfate phase rather than during a clearly defined oral magnesium L-threonate exposure summary, so that finding should be read only in that specific study context. (Research)
Interaction data are not comprehensively characterized in the cited source set. The cancer-pain trial does, however, place magnesium L-threonate in a co-treatment context with opioids, where reported outcomes included morphine dose escalation and constipation. (Research)
No direct ingredient-specific FDA source is present in the cited material used for this article, so U.S.-specific ingredient status cannot be characterized here beyond that evidence gap. (Research)
Within the EU novel-food framework, the cited EFSA source concluded that magnesium L-threonate is safe under the proposed conditions of use and that magnesium from this source is bioavailable. This cited EU safety context does not constitute drug approval or efficacy evaluation. (EFSA)
The cited European Commission application summary describes magnesium L-threonate monohydrate as a novel-food application intended for food supplements, with proposed use up to 3 g/day in that application context. Based on the cited source, this is application and framework context rather than a statement of broad EU authorization across all product categories. (EFSA)
Evidence Overview
Human evidence for magnesium L-threonate is strongest in Sleep and Cognitive Health, more mixed in Pain and Acute Inflammation, and still narrow in the cited Immune System rare-disease study. Most of the visible human literature consists of randomized placebo-controlled trials, but the overall source base is small and lacks review-level synthesis in the cited material, which is why confidence is not higher. (Research) (Research) (Research)
Randomized human trial evidence is most directly represented by the sleep and cognition studies. A 21-day trial at 1 g/day in adults with self-assessed sleep problems reported improvement in several objective sleep-stage measures and some daytime outcomes, while a 6-week trial at 2 g/day in adults with dissatisfied sleep reported improvement in several cognitive measures and some subjective sleep-related measures. These studies show that magnesium L-threonate has been directly tested in humans in these domains, but they do not establish a broad, fully replicated effect across multiple populations and endpoints. (Research) (Research)
Human evidence in Pain and Acute Inflammation is mixed across substantially different clinical settings. In advanced cancer pain, a randomized trial reported lower morphine escalation and improved opioid-related constipation, while in patients after breast cancer surgery another randomized trial reported no clear benefit for persistent pain prevention or related mood, sleep, and cognition outcomes. This evidence does not support a single consistent pain conclusion and is also limited by incomplete abstract-level dose disclosure in the cited records. (Research) (Research)
The rare-disease Immune System literature is much narrower. The cited XMEN crossover study did not report meaningful improvement in EBV burden or NKG2D expression and therefore functions more as a boundary-setting result than as a core human evidence domain. (Research)
Mechanistic and pharmacokinetic characterization are limited in the cited source set. The available EU materials add bioavailability and safety-assessment context, supporting framework-level statements that magnesium is bioavailable from this source and that the ingredient was considered safe under proposed conditions of use within the cited assessment. These sources do not replace missing long-term clinical trials, detailed human PK reporting, U.S. ingredient-specific regulatory documentation, or synthesis reviews. Future confidence would be strengthened by larger replicated randomized trials, clearer standalone dose disclosure, broader pharmacokinetic reporting, and independent review-level synthesis. (Research) (EFSA) (EFSA)
Evidence Confidence Classification
The overall human evidence for magnesium L-threonate is Limited / Mixed, based on a small number of randomized human studies with some favorable findings in Sleep and Cognitive Health, mixed results in Pain and Acute Inflammation, and important gaps in replication, synthesis coverage, and dose clarity. (Research) (Research)
Interventional human evidence is present and is the main basis for this article, but it is limited to a small trial set across different populations and outcomes. Observational human evidence is essentially absent from the cited source base, mechanistic and pharmacokinetic characterization are limited, and the regulatory context available here is mainly EU novel-food safety material rather than a broad cross-jurisdiction ingredient dossier. (Research) (EFSA)
Similar Ingredients & Comparators
- Magnesium citrate
- Magnesium glycinate
- Magnesium oxide
- Magnesium sulfate
- Magnesium chloride
- Magnesium lactate
- L-threonic acid
- Vitamin C metabolites
- Other oral magnesium salts
- Magnesium-containing clinical formulations
- Oral magnesium replacement agents
- Sleep-focused clinical interventions
- Cognitive-performance study compounds
- Adjuvant pain-management agents
- Opioid-sparing supportive care strategies
Combination Context
Magnesium L-Threonate + Opioid analgesic therapy:
This combination context was studied in advanced cancer pain, where magnesium L-threonate was added to ongoing opioid treatment. The trial examined morphine dose escalation and opioid-related constipation, reporting lower morphine-escalation requirements and less constipation in the intervention group. The main limitation is that the exact standalone oral magnesium L-threonate dose is not clearly extractable from the available source record. (Research)
Magnesium L-Threonate + Magnesium sulfate:
This is not established as a validated beneficial ingredient combination in the cited source set, but it appears as a staged exposure context in the XMEN study. Oral magnesium L-threonate was followed by 3 days of high-dose IV magnesium sulfate before open-label oral use, and no meaningful therapeutic effect was reported in the main study endpoints. (Research)
FAQ
What is this ingredient?
Magnesium L-threonate is a magnesium salt of L-threonic acid used as an oral magnesium source in human research. The cited sources treat it as a formulated compound rather than as a naturally abundant dietary ingredient consumed in ordinary foods. EU safety materials also discuss magnesium from this source as bioavailable. (Research) (EFSA)
What does human research study it for?
Human research has studied magnesium L-threonate mainly for Sleep, Cognitive Health, and selected Pain and Acute Inflammation contexts. The cited source set also includes one narrow rare-disease crossover study in XMEN disease. Most of the visible human evidence comes from randomized placebo-controlled trials rather than observational studies. (Research) (Research) (Research)
What are the best-supported uses?
The best-supported human findings in the cited source set are in Sleep and Cognitive Health because these areas have the clearest dose-defined randomized trials. Even there, the evidence remains limited because the number of studies is small and not all endpoints improve consistently across trials. Pain and Acute Inflammation evidence is less consistent across populations. (Research) (Research) (Research)
Where is evidence mixed or limited?
Evidence is mixed in Pain and Acute Inflammation contexts and limited outside the main sleep-cognition literature. One cancer-pain trial reported favorable findings, one post-breast-surgery trial reported no clear effect, and the XMEN study did not show meaningful benefit in its main outcomes. The overall evidence base is also limited by missing review-level synthesis and incomplete dose detail in some source records. (Research) (Research) (Research)
How quickly does it act (onset)?
A precise onset time is not clearly established in the cited source set. The available human trials report outcomes over 21 days, 6 weeks, 12 weeks, and 90 days, so the evidence is better for study-duration context than for exact time-to-effect estimates. That means this article can describe when outcomes were assessed, but not a validated onset curve. (Research) (Research)
What affects absorption and variability?
The cited evidence suggests that interpretation varies by population, study aim, and formulation detail. EU safety materials support magnesium bioavailability from magnesium L-threonate, but the source set does not provide a broad comparative PK literature across multiple delivery formats. Variability is also introduced because some abstracts do not clearly disclose exact standalone oral doses. (EFSA) (Research) (Research)
Is tolerance reported?
Tolerance in the sense of diminishing effect over time is not clearly characterized in the cited source set. The available trials mainly report short-term tolerability, with the sleep and cognition studies describing the intervention as well tolerated in their study populations. Longer-term adaptation patterns are not established in the cited evidence here. (Research) (Research)
Why do studies disagree?
Studies likely disagree because they examined different populations, different outcomes, and not always the same clearly disclosed dose context. Sleep-focused adults, healthy adults with dissatisfied sleep, advanced cancer patients, post-surgical patients, and patients with XMEN disease are not directly comparable clinical settings. The small size of the evidence base also means one positive or neutral study can noticeably affect the overall picture. (Research) (Research) (Research)
What ingredients is it commonly combined with and why?
The clearest cited combination context is opioid analgesic therapy, where magnesium L-threonate was studied as an add-on intervention in advanced cancer pain. Another cited co-exposure context is the XMEN protocol that included magnesium sulfate after oral magnesium L-threonate, but that was a study-design and disease-management context rather than a validated general-use ingredient combination. The cited source set does not provide a broad literature on recurring ingredient combinations. (Research) (Research)
What foods naturally contain this ingredient?
The cited sources do not describe magnesium L-threonate itself as a common natural food constituent. Instead, they discuss it as a manufactured magnesium source used in clinical and regulatory contexts. Magnesium is a nutrient found in foods, but that is not the same as naturally occurring magnesium L-threonate in ordinary dietary sources within the cited evidence here. (Research)
How is it regulated?
In the EU context covered by the cited sources, magnesium L-threonate appears in a novel-food safety and application framework rather than as a drug-approval record. EFSA concluded, within the context of the cited assessment, that the ingredient was safe under the proposed conditions of use and that magnesium from this source is bioavailable, while the European Commission document describes an application context including proposed use up to 3 g/day for food supplements. No direct ingredient-specific FDA source is present in the cited material used for this article, so U.S.-specific ingredient status cannot be characterized here beyond that evidence gap. (EFSA) (EFSA)
Resources
- Randomized trial on sleep quality and daytime functioning – PubMed – https://pubmed.ncbi.nlm.nih.gov/39252819/
- Randomized trial on cognition and sleep quality – PubMed – https://pubmed.ncbi.nlm.nih.gov/41601871/
- Randomized trial in advanced cancer pain – PubMed – https://pubmed.ncbi.nlm.nih.gov/36703238/
- Randomized trial after breast cancer surgery – PubMed – https://pubmed.ncbi.nlm.nih.gov/37520407/
- XMEN disease crossover study – PubMed – https://pubmed.ncbi.nlm.nih.gov/34655400/
- EFSA safety and bioavailability opinion – EFSA – https://www.efsa.europa.eu/en/efsajournal/pub/8656
- EFSA-linked PubMed record – PubMed – https://pubmed.ncbi.nlm.nih.gov/38481468/
- European Commission novel-food application summary – European Commission – https://food.ec.europa.eu/system/files/2021-10/novel-food_sum_ongoing-app_2021-2453.pdf
